Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Brighty, K. E.
Right arrow Articles by Gootz, T. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brighty, K. E.
Right arrow Articles by Gootz, T. D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy, Vol 39, 1-14, Copyright © 1997 by The British Society for Antimicrobial Chemotherapy

ORIGINAL ARTICLES

The chemistry and biological profile of trovafloxacin

KE Brighty and TD Gootz
Department of Medicinal Chemistry, Pfizer Inc., Groton, CT 06340, USA.

The fluoroquinolone antibacterials are noted for their activity after oral administration and potent activity against Gram-negative pathogens. Trovafloxacin (CP-99,219) is a new quinolone antibacterial characterized by a novel 3-azabicyclo[3.1.0]hexyl substituent at the C- 7 position, which was discovered in the course of a programme targeting improved activity compared with ciprofloxacin against Gram-positive aerobic organisms and anaerobes, as well as an extended elimination half-life. An overview of the chemical properties of trovafloxacin is given. Trovafloxacin exhibits excellent potency against Gram-positive organisms and anaerobes, while retaining the potent Gram-negative activity of ciprofloxacin. Its pharmacokinetic properties in humans have been shown to be compatible with a once-daily dosing regimen. The combined spectrum and pharmacokinetics of trovafloxacin have been demonstrated to result in excellent efficacy in both animal models of infections and human clinical trials. Phase II and Phase III programmes have been completed.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Arch OphthalmolHome page
I. S. Barequet, P. Denton, G. J. Osterhout, S. Tuli, and T. P. O'Brien
Treatment of Experimental Bacterial Keratitis With Topical Trovafloxacin
Arch Ophthalmol, January 1, 2004; 122(1): 65 - 69.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. J. Hecker, T. Calkins, M. E. Price, K. Huie, S. Chen, T. W. Glinka, and M. N. Dudley
Prodrugs of Cephalosporin RWJ-333441 (MC-04,546) with Improved Aqueous Solubility
Antimicrob. Agents Chemother., June 1, 2003; 47(6): 2043 - 2046.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
T. R. Anderegg, D. J. Biedenbach, and R. N. Jones
Initial Quality Control Evaluations for Susceptibility Testing of Dalbavancin (BI397), an Investigational Glycopeptide with Potent Gram-Positive Activity
J. Clin. Microbiol., June 1, 2003; 41(6): 2795 - 2796.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. B. Vakulenko, P. Taibi-Tronche, M. Toth, I. Massova, S. A. Lerner, and S. Mobashery
Effects on Substrate Profile by Mutational Substitutions at Positions 164 and 179 of the Class A TEMpUC19 beta -Lactamase from Escherichia coli
J. Biol. Chem., August 13, 1999; 274(33): 23052 - 23060.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Tranier, A.-T. Bouthors, L. Maveyraud, V. Guillet, W. Sougakoff, and J.-P. Samama
The High Resolution Crystal Structure for Class A beta -Lactamase PER-1 Reveals the Bases for Its Increase in Breadth of Activity
J. Biol. Chem., September 1, 2000; 275(36): 28075 - 28082.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.